Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
about
Recent advances in the management of mucormycosis: from bench to bedsidePosaconazole: an oral triazole with an extended spectrum of activityPosaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicansEfficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivoIn vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studiesThe susceptibility patterns of Candida species isolated from urine samples to posaconazole and caspofungin.Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.Antifungal pharmacokinetics and pharmacodynamicsSingle-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Combination therapy for mucormycosis: why, what, and how?Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Posaconazole: clinical pharmacology and potential for management of fungal infections.Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisAntifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafunginAntimicrobial dosing in acute renal replacement.Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolatesIsavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antifungal therapeutic drug monitoring: established and emerging indications.Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.Safety of triazole antifungal drugs in patients with cancer.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.Posaconazole: when and how? The clinician's view.Current concepts in antifungal pharmacology.
P2860
Q24642450-3B72C309-9DBD-4646-9B8B-251C32B64697Q28291282-9E251C5C-E65A-495A-9A9E-626586AA1DA1Q28487653-6D08FC41-D59F-4946-AE68-512079664ABFQ33613758-F9217D71-0BD9-4DCB-BAD7-8DE39616F1CBQ33803508-1D5F5C22-2BCD-409F-9388-2917799EA7D3Q33876423-DEBADFA7-B318-44E1-AD90-F9FF2C95D5EFQ33938082-28A8AEF8-DE9F-47A7-AC1E-CBBEA2ABC632Q34077069-AAA465B4-CDA3-45DB-B5E7-6AB3876EF583Q34108650-49EBE660-67FC-4A5B-B588-A912B3EBA67FQ34596761-8059463E-8DBF-4A76-8654-07D5B63A1851Q34721750-F2BF68F6-B5AB-4A82-B48D-99792AE56EF0Q35026481-7326FF12-0F21-4B90-8DC9-B4422E59132BQ35113648-47A7CCBE-7BA5-412D-B684-A093F6CE98B1Q35276302-31F9EA98-B65F-49C5-8BFF-626C861B97A2Q35635693-650F5062-F385-442D-A5C9-A5181C815C56Q35663841-CA671C83-4EBA-41A7-8C3A-5B91163218ACQ35912756-8CAD0CC4-DC4F-4226-9848-CDC0598A4093Q35973357-E5C25899-8C8E-44E4-ADA2-5C59D17F6030Q35974333-77A716EC-64DB-46C4-A99E-BC495792BE1AQ36018743-8D121DD4-274D-4831-AB04-7287CB7EA4FCQ36233491-8036D2DA-67C0-41FA-891B-A898ADCADEB8Q36364100-87D9D16A-A1B1-461B-9DB3-A3543D863D4EQ36482785-50C9F3B1-B6C4-4534-BC36-6BD2EE97AA3DQ36505539-882F96FA-B168-4772-8307-27CA54970351Q36589297-A498B7C4-50C6-4B1F-8E54-2E44092EF266Q37055215-18FB842D-E454-42E6-BB51-83C9E08E55CDQ37072036-2C737C71-64CE-400F-9621-4A4081D4792EQ37190801-B9E5A3F2-0DF2-456A-8720-0D584DA3EA65Q37252494-37F01DAE-BDEA-483F-A1FA-6A4C91814A5AQ37263430-A8F1F3CA-F456-49F4-BF0E-A606019320E4Q37263435-9B9D3ED6-19EF-48C6-B2A0-D5A04071B03BQ37310029-20C0DA18-7F15-4719-BCC7-3844D26EF795Q37356974-B711355D-AEA1-4E78-925F-B313BE430335Q37404840-DF530D81-3AB8-45FE-9260-08721CF2539DQ37568382-D0648326-9CD2-417D-96A3-AE939B53BDC8Q37662650-7A6A904A-1F78-48C5-BDAC-976141775098Q37688257-6640C800-8CAE-462A-9055-0880BE567620Q37713035-D7006E46-EA27-47A5-97FA-0E82F60DFFC1Q37901534-0257DDCA-6748-489F-A3C8-1F2AA1A59AACQ37908856-12E69D8A-B0CB-4D90-A42C-3D979618E67F
P2860
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pharmacodynamics of a new tria ...... el of disseminated candidiasis
@ast
Pharmacodynamics of a new tria ...... el of disseminated candidiasis
@en
type
label
Pharmacodynamics of a new tria ...... el of disseminated candidiasis
@ast
Pharmacodynamics of a new tria ...... el of disseminated candidiasis
@en
prefLabel
Pharmacodynamics of a new tria ...... el of disseminated candidiasis
@ast
Pharmacodynamics of a new tria ...... el of disseminated candidiasis
@en
P2093
P2860
P1476
Pharmacodynamics of a new tria ...... el of disseminated candidiasis
@en
P2093
Anthony Cacciapuoti
David Loebenberg
Farkad Ezzet
Gopal Krishna
K Marchillo
P2860
P304
P356
10.1128/AAC.48.1.137-142.2004
P407
P50
P577
2004-01-01T00:00:00Z